SAN DIEGO--(BUSINESS WIRE)--
Symbiotica® Inc, a CLIA-certified clinical laboratory, and InTeleLabs®, Inc., a telehealth and personalized medicine company, announced today they have launched their Serology COVID-19 Immune Response Antibody test, the first at-home self-collection antibody test for children and adults using a small amount of blood from a simple finger pinprick. This milestone is a first in the US market as consumers, with oversight from licensed healthcare professionals, now have the ability to purchase, collect, and receive results for a COVID-19 test all from the safety, privacy, and comfort of home.
“We are excited to be the first to offer an accurate home collection antibody test as the nation continues to fight this deadly virus,” said Erik Hennings, CEO of InTeleLabs. “Our test is an important tool to help identify children and adults who have been infected with the virus and developed an immune response to COVID-19. Whether or not an individual received a diagnosis or experienced symptoms, knowing if one has antibodies will be important as we begin to make decisions about returning to work, school, and the new normal.”
“It is most likely that 50% or more of people who have been infected with COVID-19 may not have displayed noticeable symptoms, making it difficult to identify them as positive for COVID-19,” said Susan Zneimer, PhD, FACMGG, Co-CEO of Symbiotica. “That is why serological testing which uses an antigen that is highly specific to SARS-CoV-2 is such an important tool for us to understand how pervasive this virus is in our communities. At Symbiotica, we believe in having COVID-19 tests available for everyone, and what better way to do that than to provide testing that can be ordered through telemedicine and self-sampling. This is one way to bring peace of mind to the people of our communities.”
Highly accurate, easy-to-use, finger pinprick test
The COVID-19 Immune Response Antibody test detects immunoglobulin G (IgG) antibodies and has a 90% sensitivity and 100% specificity after 21 days following the onset of symptoms. The test can determine who had previously been infected with COVID-19 (2-4 weeks or more prior to testing) and may have developed immunity. How long antibodies last and whether they are protective is being actively studied. The testing process was designed to be easy-to-use by obtaining small blood droplets collected on a dried blood spot (DBS) card from a simple, finger pinprick test.
Available from the safety, privacy, and comfort of your home
The ability for people to test from home is an important milestone in expanding COVID-19 testing capabilities, reducing strain on the healthcare system, and minimizing the risk of additional exposure. The test is available through InTeleLabs’ elicity® web-based platform. elicity is an online, telehealth platform empowering patients with access to at-home clinically validated lab testing, accurate results delivered online, and oversight from licensed healthcare professionals.
Symbiotica is a CLIA-certified clinical laboratory that provides high quality, diversified, personalized testing and laboratory services for patient-care companies. We develop partnerships with companies in order to improve the health and well-being of individuals. More information about the COVID-19 testing and other laboratory tests can be found at https://www.symbioticainc.com.
InTeleLabs is a telehealth and personalized medicine company, ensuring that high quality, clinical lab testing is accessible and convenient through its proprietary, HIPAA-compliant online telehealth platform, elicity®. elicity works by connecting patients with independent, licensed healthcare professionals to oversee the selection, ordering, and delivery of clinically validated lab tests, empowering patients to take control of their health. For more information about the COVID-19 Immune Response Antibody test, or other available lab tests on elicity, visit https://www.elicity.health.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005297/en/
Copyright Business Wire 2020